CTXR - Company ID 0001506251
The table below shows Citius Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $90.00K | $90.00K | $90.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.16M | $11.91M | $14.82M | $17.66M | $12.24M | $8.81M |
| SG&A |
Citius Pharmaceuticals, Inc. reported annual revenue of $90.00K for fiscal year 2022. That is up 0.0% from $90.00K in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $18.53M |
| $18.25M |
| $15.30M |
| $11.75M |
| $9.84M |
| $8.09M |
| Operating income | -$38.53M | -$42.00M | -$36.73M | -$33.32M | -$23.53M | -$17.71M |
| Income tax | $1.06M | $576.00K | $576.00K | $576.00K | $1.23K | $741.00 |
| Net income | - | - | -$32.54M | -$33.64M | -$23.05M | -$17.55M |
| EPS (diluted) | -$3.38 | -$5.97 | -$5.57 | -$0.23 | -$0.23 | - |